logo

EVMN

EvommuneยทNYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

EVMN Profile

Evommune, Inc.

A U.S.biotech company focused on diseases such as urticaria and atopic dermatitis,with tissue genetics as the core of its R&D,holding multiple clinical-stage therapies

Pharmaceutical
--
11/06/2025
New York Stock Exchange
45
12-31
Common stock
1841 Page Mill Road Suite 100 Palo Alto CA 94304
--
Evommune, Inc., a Delaware corporation incorporated in April 2020, is headquartered in Palo Alto, California. The company is a clinical-stage biotechnology company focused on the development of innovative treatments for the main pathogenic factors of chronic inflammatory diseases. Its initial clinical development projects focus on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis.